Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
The latest update is out from MaxCyte ( (MXCT) ).
MaxCyte, Inc. announced the issuance of 4,814 shares of common stock as part of its block admission facility, following the exercise of share options and vesting of restricted stock units. This brings the company’s total issued stock capital to 106,318,532 shares. This update is significant for shareholders as it affects the calculations for determining changes in their stock interests.
More about MaxCyte
MaxCyte, Inc. is a leading company in the cell-engineering industry, focusing on platform technologies that advance the discovery, development, and commercialization of next-generation cell-based therapeutics. Their ExPERT™ platform, which utilizes Flow Electroporation® technology, supports the cell therapy market from discovery through commercialization. The company offers a range of instruments, processing assemblies, and software protocols, all backed by a strong intellectual property portfolio.
YTD Price Performance: -33.95%
Average Trading Volume: 32,343
Technical Sentiment Signal: Buy
Current Market Cap: £223.2M
Learn more about MXCT stock on TipRanks’ Stock Analysis page.